Interim Results 2020

First half results ahead of COVID-19 plan. Revenue and profitability expected to continue to improve in the second half.

Scapa Group Ltd (AIM: SCPA), the diversified Healthcare and Industrial company focused on bringing best-in-class innovation, design and manufacturing solutions to its customers, today announces its unaudited financial results for the six-month period ended 30 September 2020.

Group Financial Highlights:

- As previously disclosed in the October trading update, revenue declined 24.1% to £122.0m (2019: £160.8m)
- Revenue improved 23.0% sequentially from Q1 to Q2 as demand begins to return to prior year level
- Trading profit1 of £5.5m (2019: £14.2m) impacted by reduced volumes but offset by targeted cost savings and government subsidies
- Basic loss per share improved to 0.2p (2019: loss of 0.6p)
- Adjusted net debt2 reduced to £21.8m (31 March 2020: £54.4m) due to reduction of working capital and net proceeds from the equity placement in May 2020 of £31.6m
- Net debt reduced to £40.4m (31 March 2020: £74.6m) includes IFRS 16 impact of £18.6m
- Bank net debt / EBITDA3 of 0.7x

Division Highlights


- Demand across the segments has been impacted by the postponement of elective surgeries and reduced footfall across the retail channels; early signs of improvement in Q3, albeit cautious given the recent global resurgence of COVID-19 infections
- Revenue decreased 26.2% to £55.1m (2019: £74.7m) with declines seen in Wound Care and Medical Devices
- Consumer grew 2.9% driven by two technology transfers completed last year
- Trading profit1 decreased to £1.3m (2019: £6.6m); impacted by lower volume but offset by targeted cost control measures and government subsidies
- Completed planned consolidation of Dunstable and Inglewood sites into Gargrave and Knoxville, respectively; cost benefit from right-sizing expected in H2


- Revenue decreased 22.3% to £66.9m (2019: £86.1m); demand has recovered to pre-COVID-19 levels at the end of Q2, which is expected to positively impact revenues in H2
- The recovery from Q1 has been seen across all segments and geographies particularly in Construction and Automotive
- Trading profit1 decreased to £6.1m (2019: £10.2m); impacted by lower volume but offset by a positive product mix and targeted cost control measures
- New programme wins in Automotive, Cable and Consumer
- Product expansion, including facemasks, antibacterial wipes and eco-friendly roofing solutions, reflecting, as detailed in the full year results, the Company’s flexibility to respond to market needs

Outlook Highlights:

- Return to pre-COVID-19 demand levels in Industrial and encouraging progress in Healthcare are driving momentum
- Whilst uncertainty remains given the recent global resurgence of COVID-19 infections, revenue in both divisions in H2 is expected to exceed H1, with earnings benefitting from additional volumes and cost improvement programmes already implemented
- As a result of this momentum, we continue to track ahead of our COVID plan

1 Profit before net finance costs, exceptional items, amortisation of intangible assets, acquisition costs and legacy pension costs
2 Adjusted net debt excludes lease liabilities
3 EBITDA comprises trading profit before depreciation for the last 12 months
4 Adjusting operating profit and taxation for exceptional items, pension administration costs, amortisation and non-cash interest
5 Group results before the impact of IFRS 15 provision release for the Systagenix acquisition

Commenting on the results Group Chief Executive, Heejae Chae said:

"We delivered first half results ahead of our COVID-19 plan and the Board’s expectations, demonstrating the herculean effort by everyone in the organisation in response to the pandemic. As a designated essential business, we have maintained operations throughout the pandemic and supported our commercial partners thanks to the dedication of our colleagues around the world. The swift actions we took at the beginning of the pandemic have helped to mitigate effects on our profitability and cash generation, as well as to continue to service our customers. As demand returns to pre-COVID-19 levels, we have the agility to meet this demand, positioning us well to capture additional market share. We have taken strategic and operational actions to position us better both in terms of profitability and to further strengthen the Balance Sheet. Whilst mindful of the recent global resurgence of COVID-19 infections, we expect that revenue and profitability will continue to improve during the second half of the financial year."


For further information:

Scapa Group Ltd

Heejae Chae – Group Chief Executive

Oskar Zahn – Chief Financial Officer

Tel: 0161 301 7430

Numis Securities Limited

(Nominated Adviser/Joint Broker)

Mark Lander, Freddie Barnfield

Tel: 020 7260 1000

Berenberg (Joint Broker)

Chris Bowman, Toby Flaux

Tel: 020 3207 7800

FTI Consulting (Media Relations)

Brett Pollard, Victoria Foster Mitchell

Tel: 020 3727 1000


About Scapa Group Ltd

Scapa Group Ltd is a diversified Healthcare and Industrial company focused on bringing best-in-class innovation, design and manufacturing solutions to its customers.


Scapa Healthcare is the trusted strategic partner of choice for the world's leading companies in Advanced Wound Care, Consumer Wellness and Medical Device Fixation. We partner with the top global MedTech companies to develop and manufacture innovative skin friendly medical device fixation and topical solutions, from inception through to market delivery, from our state-of-the-art facilities.

For further information, please visit


Scapa Industrial is a global supplier of bonding solutions and manufacturer of adhesive-based products which offer meaningful value in industrial applications due to their lightweight, easy-to-apply properties. We are recognised for our unparalleled range of products, including adhesive tapes, films and foams, and we can engineer custom designs for even the most unique applications.

For further information, please visit

For full press release and presentation see Results and Presentations